The Serious Threat of Venous Thromboembolism (VTE)
leading cause of vascular death in the world1
0
rd
patients in the U.S. affected each year2
9
K
mortality for pulmonary embolism within the first month of diagnosis3–4
0
%
of patients with deep vein thrombosis will eventually have a pulmonary embolism (PE)5
>
0
%
Intelligent | Efficient | Predictable
360° Directional Aspiration
TrueClot ™ Sensing
Integrated Dilator & Navigation Catheter
Inline Blood Return
Remove Clot | Return Blood | One Catheter | Full Control
The AVENTUS Thrombectomy System offers optimal efficiency, real-time tissue sensing, and integrated blood return – advancing PE intervention through intelligent design.
Intelligent Tip Design
Integrated Blood Return
TrueClot™ Sensing
No Capital Equipment
AVENTUS Data Preview
Featuring Dr. Jun Li, Dr. Mehdi Shishehbor, Dr. Saher Sabri
Scott’s Journey to Recovery
How AVENTUS Made a Difference
Latest News
Inquis Medical Launches a Large Multicenter Post-Market Registry to Build on Positive AVENTUS™ Pivotal Trial Results with Real-World Evidence in Pulmonary Embolism
All-comer SENSE-PE registry will enroll up to 600 patients at up to 60 U.S. sites, measuring AVENTUS performance in everyday
Inquis Medical Launches First Thrombectomy Catheter with Full 360° Directional Aspiration for Pulmonary Embolism
AVENTUS Catheter combines 360° directional aspiration, TrueClot™ tissue sensing, and autologous blood return for exceptional control over clot removal MENLO
Inquis Medical Announces $75 Million Series C Financing to Scale Commercial Adoption of its AVENTUS Thrombectomy System
Strategic investment follows a transformative year marked by the national launch of the AVENTUS thrombectomy system. MENLO PARK, Calif.–(BUSINESS WIRE)–Inquis